{"id":303,"date":"2026-02-18T16:12:56","date_gmt":"2026-02-18T14:12:56","guid":{"rendered":"http:\/\/example.test\/?post_type=product&#038;p=303"},"modified":"2026-09-10T10:51:59","modified_gmt":"2026-09-10T07:51:59","slug":"semaglutide-10-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/ro\/product\/semaglutide-10-mg\/","title":{"rendered":"Semaglutid\u0103 10 mg"},"content":{"rendered":"<p><strong>Semaglutid\u0103 <\/strong><strong>10 mg in Europe | <\/strong><em>Dori\u021bi s\u0103 cump\u0103ra\u021bi semaglutid\u0103 \u00een Europa? Life Peptide furnizeaz\u0103 semaglutid\u0103 de \u00eenalt\u0103 puritate pentru cercetare de laborator, cu livrare fiabil\u0103 \u00een toat\u0103 Uniunea European\u0103.<\/em><\/p>\n<h4><strong>Available in two formats<\/strong><\/h4>\n<p><em>Choose between a conventional lyophilized vial and a dual-chamber cartridge.<\/em><\/p>\n<p>The cartridge keeps Semaglutide and its diluent in separate chambers until activation. This avoids transporting the peptide as a premixed solution and simplifies laboratory preparation by removing the separate liquid-transfer step. Final dual-chamber cartridge concentration: 10 mg in 1 mL. A compatible reusable device is required.<\/p>\n<hr \/>\n<p>Semaglutida este o <strong>agonist al receptorului de GLP-1 cu ac\u021biune prelungit\u0103<\/strong> conceput pentru a imita activitatea peptidului-1 similar glucagonului endogen, oferind \u00een acela\u0219i timp o activitate biologic\u0103 substan\u021bial mai lung\u0103 dec\u00e2t hormonul nativ. Spre deosebire de <a href=\"https:\/\/life-peptide.com\/ro\/product\/tirzepatide-10-mg\/\">Tirzepatid\u0103<\/a> \u0219i <a href=\"https:\/\/life-peptide.com\/ro\/product\/retatrutide-10-mg\/\">Retatrutid\u0103<\/a>, Semaglutida activeaz\u0103 doar receptorul GLP-1, fiind cel mai simplu membru al genera\u021biei actuale de peptide incretinice. Acest mecanism selectiv a f\u0103cut ca Semaglutida <strong>unul dintre cele mai amplu investigate peptide metabolice<\/strong> at\u00e2t \u00een cercetarea preclinic\u0103, c\u00e2t \u0219i \u00een cea clinic\u0103 din ultimul deceniu.<\/p>\n<p>Din cauza acestei mari cantit\u0103\u021bi de dovezi, Semaglutida este utilizat\u0103 frecvent ca <strong>compusul de referin\u021b\u0103<\/strong> la evaluarea noilor agonisti cu receptor dual \u0219i triplu.<\/p>\n<hr \/>\n<h4><strong>De ce Semaglutida r\u0103m\u00e2ne important\u0103 \u00een cercetarea metabolic\u0103<\/strong><\/h4>\n<p>De\u0219i noile agoni\u0219ti cu multi-receptori au atras o aten\u021bie considerabil\u0103, Semaglutida continu\u0103 s\u0103 serveasc\u0103 drept reper \u0219tiin\u021bific pentru biologia GLP-1.<\/p>\n<p>Cercet\u0103rile publicate au investigat Semaglutida \u00een leg\u0103tur\u0103 cu:<\/p>\n<ul>\n<li><strong>reglarea apetitului<\/strong><\/li>\n<li><strong>reducerea greut\u0103\u021bii corporale<\/strong><\/li>\n<li><strong>control glicemic<\/strong><\/li>\n<li><strong>secre\u021bie de insulin\u0103<\/strong><\/li>\n<li><strong>golire gastric\u0103<\/strong><\/li>\n<li><strong>rezultate cardiovasculare<\/strong><\/li>\n<li><strong>sindrom metabolic<\/strong><\/li>\n<li><strong>boapt\u0103 hepatic\u0103 non-alcoolic\u0103<\/strong><\/li>\n<li><strong>semnalizare incretinic\u0103 pe termen lung<\/strong><\/li>\n<\/ul>\n<p>Literatura sa clinic\u0103 extins\u0103 face din Semaglutid\u0103 una dintre cele mai importante molecule de compara\u021bie \u00een cercetarea obezit\u0103\u021bii \u0219i a metabolismului. Multe studii moderne care evalueaz\u0103 Tirzepatid\u0103, Retatrutid\u0103 \u0219i combina\u021biile emergente de GLP-1 folosesc Semaglutida ca <strong>standardul de referin\u021b\u0103<\/strong>.<\/p>\n<h4><strong>Cum ac\u021bioneaz\u0103 semaglutida<\/strong><\/h4>\n<p>Semaglutid\u0103 <strong>activeaz\u0103 selectiv receptorul GLP-1<\/strong>, un regulator cheie al apetitului, al homeostaziei glucozei \u0219i al semnaliz\u0103rii gastrointestinale.<\/p>\n<p>Activarea receptorilor GLP-1 a fost asociat\u0103 \u00een cercet\u0103rile publicate cu:<\/p>\n<ul>\n<li>secre\u021bie de insulin\u0103 dependent\u0103 de glucoz\u0103<\/li>\n<li>inhibarea eliber\u0103rii de glucagon<\/li>\n<li>evacuare gastric\u0103 \u00eent\u00e2rziat\u0103<\/li>\n<li>consum redus de alimente<\/li>\n<li>semnalare central\u0103 modificat\u0103 a apetitului<\/li>\n<li>\u00eembun\u0103t\u0103\u021biri ale mai multor markeri metabolici<\/li>\n<\/ul>\n<p>Spre deosebire de Tirzepatid, Semaglutida face <strong>nu<\/strong> activeaz\u0103 receptorii GIP. Spre deosebire de Retatrutide, acesta are <strong>f\u0103r\u0103 glucagon<\/strong> activitatea receptorilor.<\/p>\n<p>Valoarea sa const\u0103, a\u0219adar, \u00een furnizarea unei caracteriz\u0103ri clare <strong>model GLP-1 cu cale unic\u0103<\/strong>, f\u0103c\u00e2ndu-l comparatorul logic pentru compu\u0219ii incretinici mai noi.<\/p>\n<h4><strong>Descoperiri clinice publicate privind Semaglutida<\/strong><\/h4>\n<p>Semaglutida are una dintre <strong>cea mai mare dovad\u0103 uman\u0103<\/strong> bazele oric\u0103rui peptid\u0103 utilizat \u00een prezent \u00een cercetarea metabolic\u0103.<\/p>\n<p>\u00cen cadrul programului clinic STEP, semaglutida administrat\u0103 o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 a produs <strong>reduceri substan\u021biale ale greut\u0103\u021bii corporale<\/strong> de-a lungul unor perioade de tratament de peste 68 de s\u0103pt\u0103m\u00e2ni, stabilind agonismul receptorilor GLP-1 ca o strategie terapeutic\u0103 major\u0103 pentru cercetarea obezit\u0103\u021bii.<\/p>\n<p>Dincolo de rezultatele legate de greutate, multiple programe clinice de amploare au demonstrat \u00eembun\u0103t\u0103\u021biri \u00een:<\/p>\n<ul>\n<li>HbA1c<\/li>\n<li>glicemie a jeun<\/li>\n<li>circumferin\u021ba taliei<\/li>\n<li>tensiune arterial\u0103<\/li>\n<li>rezultate cardiovasculare selectate<\/li>\n<li>markeri de risc cardiometabolic<\/li>\n<\/ul>\n<p>Deoarece aceste rezultate au fost reproduse \u00een numeroase studii independente, Semaglutida r\u0103m\u00e2ne <strong>principalul reper<\/strong> fa\u021b\u0103 de care sunt evaluate noile peptide cu agonist dual \u0219i triplu.<\/p>\n<h4><strong>Publicat concluzii privind siguran\u021ba \u0219i tolerabilitatea<\/strong><\/h4>\n<p>Studiile clinice publicate identific\u0103 \u00een mod constant evenimentele gastrointestinale ca fiind cele mai frecvente efecte adverse asociate cu Semaglutida. Evenimentele raportate frecvent includ: grea\u021b\u0103, v\u0103rs\u0103turi, diaree, constipa\u021bie \u0219i disconfort abdominal.<\/p>\n<p>\u00cen cadrul programelor clinice majore, aceste evenimente au fost \u00een general cele mai pronun\u021bate \u00een timpul <strong>escaladarea dozei<\/strong> \u0219i erau descri\u0219i de obicei ca <strong>u\u0219or spre moderat<\/strong> ca severitate. Ca \u0219i \u00een cazul altor agoni\u0219ti ai receptorilor GLP-1, cre\u0219terea treptat\u0103 a dozelor a fost o component\u0103 important\u0103 a protocoalelor de cercetare publicate, utilizat\u0103 pentru a \u00eembun\u0103t\u0103\u021bi tolerabilitatea.<\/p>\n<p>Aceast\u0103 sec\u021biune rezum\u0103 concluziile publicate privind cercetarea investiga\u021bional\u0103 \u0219i clinic\u0103 a semaglutidei \u0219i nu este destinat\u0103 ca \u00eendrumare pentru utilizarea acestui produs.<\/p>\n<h4><strong>Schemele de dozaj publicate utilizate \u00een cercetarea privind semaglutida<\/strong><\/h4>\n<p>Studiile publicate privind semaglutida au utilizat, \u00een general, administrarea o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103, cu escaladarea treptat\u0103 a dozelor, permi\u021b\u00e2nd investigatorilor s\u0103 evalueze at\u00e2t eficacitatea, c\u00e2t \u0219i tolerabilitatea gastrointestinal\u0103 pe perioade extinse de tratament.<\/p>\n<p>\u00cen cadrul programelor majore pentru obezitate \u0219i diabet, <strong>protocoale de escaladare<\/strong> au fost utilizate \u00eenainte de atingerea dozelor de \u00eentre\u021binere, studiile continu\u00e2nd p\u00e2n\u0103 la 68 de s\u0103pt\u0103m\u00e2ni \u00een cercetarea obezit\u0103\u021bii. Literatura publicat\u0103 reflect\u0103, a\u0219adar, un design clinic structurat al studiului, mai degrab\u0103 dec\u00e2t o singur\u0103 schem\u0103 de dozare universal\u0103.<\/p>\n<table style=\"height: 174px;\" width=\"698\">\n<thead>\n<tr>\n<td><strong>Contextul studiului publicat<\/strong><\/td>\n<td><strong>Designul studiului<\/strong><\/td>\n<td><strong>Frecven\u021b\u0103<\/strong><\/td>\n<td><strong>Durat\u0103<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Programul de obezitate STEP<\/td>\n<td>cre\u0219tere treptat\u0103 a dozei<\/td>\n<td>o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103<\/td>\n<td>68 de s\u0103pt\u0103m\u00e2ni<\/td>\n<\/tr>\n<tr>\n<td>Programul de diabet SUSTAIN<\/td>\n<td>cre\u0219tere treptat\u0103 a dozei<\/td>\n<td>o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103<\/td>\n<td>variat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Aceste programe rezum\u0103 cercetarea clinic\u0103 publicat\u0103 privind designul \u0219i nu reprezint\u0103 instruc\u021biuni de utilizare a acestui produs.<\/p>\n<h4><strong>Semaglutide vs Tirzepatide vs Retatrutide<\/strong><\/h4>\n<p><strong>Semaglutid\u0103<\/strong><\/p>\n<ul>\n<li>agonist al receptorilor GLP-1<\/li>\n<li><strong>singur<\/strong> mecanism receptor<\/li>\n<li>cea mai mare baz\u0103 de dovezi clinice<\/li>\n<li>compus de referin\u021b\u0103 pentru cercetarea GLP-1<\/li>\n<\/ul>\n<p><strong>Tirzepatid\u0103<\/strong><\/p>\n<ul>\n<li>GLP-1 + GIP <strong>dublu<\/strong> agonist<\/li>\n<li>semnalizare incretinic\u0103 mai extins\u0103<\/li>\n<li>comparat frecvent direct cu Semaglutida<\/li>\n<\/ul>\n<p><strong>Retatrutid\u0103<\/strong><\/p>\n<ul>\n<li>GLP-1 + GIP + glucagon <strong>triplu<\/strong> agonist<\/li>\n<li>cel mai larg profil de receptori<\/li>\n<li>reprezint\u0103 cea mai nou\u0103 genera\u021bie de peptide metabolice cu multi-receptori<\/li>\n<\/ul>\n<p>Pentru cercet\u0103torii care investigheaz\u0103 biologia incretinelor, Semaglutida ofer\u0103 baza de la care pot fi evaluate compu\u0219ii cu agonist dual \u0219i triplu.<\/p>\n<h4><strong>Caracteristicile produsului<\/strong><\/h4>\n<p>Aplica\u021bie: cercetare de laborator \u0219i analitic\u0103<br \/>\nA nu se consuma de c\u0103tre oameni; nu pentru uz medical, veterinar sau cosmetic<br \/>\nProdus \u00een facilit\u0103\u021bi conforme GMP, sub protocoale stricte de control al calit\u0103\u021bii.<br \/>\nFiecare lot este testat cu aten\u021bie \u00een laborator dup\u0103 produc\u021bie (pute\u021bi g\u0103si Certificatul de Analiz\u0103 sub imaginile produsului).<br \/>\nLiofilizat (uscat prin congelare) pentru stabilitate maxim\u0103 \u0219i termen de valabilitate extins.<br \/>\nSigilate \u00een fiole sterile, gata pentru reconstituire.<br \/>\nPuritate: \u226599% (testat prin HPLC)<br \/>\nAspect: Pulbere alb\u0103\/albicioas\u0103 liofilizat\u0103<br \/>\nFormula molecular\u0103: C<sub>187<\/sub>H<sub>291<\/sub>N<sub>45<\/sub>O<sub>59<\/sub><br \/>\nMas\u0103 molecular\u0103: 4113.64<br \/>\nSecven\u021b\u0103: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-\u03b3-Glu-17-carboxiheptadecanoil)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly<br \/>\n<strong>Depozitare<\/strong>: fiolele liofilizate nedeschise sunt cel mai bine p\u0103strate <strong>refrigerat la 2\u20138\u00b0C<\/strong>, care este metoda de stocare confirmat\u0103 de partenerul nostru de produc\u021bie \u0219i potrivit\u0103 pentru p\u00e2n\u0103 la 24 de luni. Se prefer\u0103 refrigerarea deoarece minimizeaz\u0103 ciclurile inutile de \u00eenghe\u021b-dezghe\u021b \u00een timpul manipul\u0103rii de rutin\u0103. Dac\u0103 este necesar\u0103 o depozitare pe termen mult mai lung, fiolele liofilizate nedeschise pot fi p\u0103strate \u0219i congelate. Dup\u0103 reconstituire, depozita\u021bi \u00eentotdeauna la 2\u20138\u00b0C \u0219i nu congela\u021bi.<\/p>\n<h4><strong>Reconstituire \u0219i manipulare<\/strong><\/h4>\n<p>Semaglutide este furnizat sub form\u0103 de flacon liofilizat \u0219i trebuie manevrat utiliz\u00e2nd procedurile standard de reconstituire a peptidei adecvate mediului de cercetare. Trebuie reconstituit cu <a href=\"https:\/\/life-peptide.com\/ro\/product\/bac-10-ml\/\">ap\u0103 bacteriostatic\u0103<\/a> \u00cenainte de utilizare. Peptidele din clasa GLP-1 se dizolv\u0103 uneori lent \u0219i necesit\u0103 o reconstituire foarte delicat\u0103 pentru a evita formarea de spum\u0103 sau r\u0103m\u00e2nerea u\u0219or tulbure.<\/p>\n<p>Pentru alte informa\u021bii despre selec\u021bia solven\u021bilor, planificarea concentra\u021biei \u0219i depozitare, consulta\u021bi complet <a href=\"https:\/\/life-peptide.com\/ro\/reconstitution-of-peptides\/\">Ghid de Reconstituire a Peptidelor<\/a> \u0219i <a href=\"https:\/\/life-peptide.com\/ro\/calculator\/\">Calculator de Reconstituire<\/a>.<\/p>\n<h4>Studii cheie publicate<\/h4>\n<ul>\n<li>Wilding JPH et al. \u201c<em>Semaglutida administrat\u0103 o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 la adul\u021bii cu supraponderabilitate sau obezitate.\u201d New England Journal of Medicine<\/em>, 2021.<\/li>\n<li>Frias JP, Davies MJ, Rosenstock J, et al.\u00a0<em>Tirzepatide versus semaglutid administrat o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 la pacien\u021bii cu diabet zaharat de tip 2 (SURPASS-2). New England Journal of Medicine<\/em>. 2021.<\/li>\n<li>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.\u00a0<em>Semaglutida \u0219i rezultatele cardiovasculare \u00een obezitate f\u0103r\u0103 diabet (SELECT). New England Journal of Medicine<\/em>. 2023.<\/li>\n<li>Aroda VR.\u00a0<em>O revizuire a programului de studii clinice SUSTAIN. Diabetes, Obesity and Metabolism<\/em>. 2019.<\/li>\n<\/ul>\n<hr \/>\n<h4><strong>\u00centreb\u0103ri Frecvente<\/strong><\/h4>\n<p><strong>Ce este Semaglutida?<\/strong><\/p>\n<p>Semaglutida este un agonist al receptorilor GLP-1 cu ac\u021biune prelungit\u0103, care mimeaz\u0103 activitatea hormonului incretinic natural glucagon-like peptide-1. A devenit unul dintre cele mai amplu studiate peptide metabolice \u0219i serve\u0219te drept compus de referin\u021b\u0103 pentru cercetarea modern\u0103 \u00een domeniul GLP-1. Studiile publicate au investigat semaglutida \u00een leg\u0103tur\u0103 cu reglarea apetitului, homeostazia glucozei, rezultatele privind greutatea corporal\u0103 \u0219i semnalizarea cardiometabolic\u0103 mai ampl\u0103.<\/p>\n<p><strong>Cum ac\u021bioneaz\u0103 Semaglutida?<\/strong><\/p>\n<p>Semaglutida activeaz\u0103 selectiv receptorul GLP-1, o cale implicat\u0103 \u00een reglarea secre\u021biei de insulin\u0103, a eliber\u0103rii de glucagon, a golirii gastrice \u0219i a semnaliz\u0103rii apetitului. Spre deosebire de agoni\u0219tii duali \u0219i tripli de receptori mai noi, ea ac\u021bioneaz\u0103 doar asupra receptorilor GLP-1, ceea ce o face o molecul\u0103 de referin\u021b\u0103 important\u0103 pentru cercet\u0103torii care compar\u0103 diferite strategii terapeutice bazate pe incretin\u0103.<\/p>\n<p><strong>Cum difer\u0103 Semaglutida de Tirzepatid\u0103?<\/strong><\/p>\n<p>Semaglutida activeaz\u0103 doar receptorul GLP-1, \u00een timp ce Tirzepatida este un agonist dual GLP-1\/GIP. Ambii compu\u0219i apar\u021bin clasei incretinelor, dar Tirzepatida extinde mecanismul dincolo de semnalizarea GLP-1. Ca urmare, Semaglutida este adesea utilizat\u0103 ca etalon \u00een raport cu care sunt evalua\u021bi agoni\u0219tii duali \u00een cercetarea metabolic\u0103.<\/p>\n<p><strong>Cum difer\u0103 Semaglutida de Retatrutid\u0103?<\/strong><\/p>\n<p>Retatrutida este un agonist triplu care are ca \u021bint\u0103 receptorii GLP-1, GIP \u0219i glucagon, conferindu-i cel mai larg profil de receptori aflat \u00een prezent \u00een investiga\u021bie printre peptidele incretinice. Semaglutida, prin contrast, se concentreaz\u0103 exclusiv pe activarea receptorului GLP-1. Acest lucru face ca Semaglutida s\u0103 fie molecula de referin\u021b\u0103 fundamental\u0103 pentru biologia GLP-1, \u00een timp ce Retatrutida reprezint\u0103 noua genera\u021bie de cercetare metabolic\u0103 cu receptori multipli.<\/p>\n<p><strong>De ce este Semaglutida \u00eenc\u0103 important\u0103, de\u0219i exist\u0103 peptide mai noi?<\/strong><\/p>\n<p>De\u0219i noile peptide cu ac\u021biune dual\u0103 \u0219i tripl\u0103 agonist\u0103 au st\u00e2rnit un interes considerabil, Semaglutida r\u0103m\u00e2ne unul dintre cei mai importan\u021bi compu\u0219i \u00een cercetarea metabolic\u0103, deoarece de\u021bine cel mai mare \u0219i mai matur volum de dovezi clinice publicate. Multe studii care evalueaz\u0103 Tirzepatida, Retatrutida \u0219i alte peptide aflate \u00een investiga\u021bie continu\u0103 s\u0103 foloseasc\u0103 Semaglutida ca principal comparator, ceea ce o face esen\u021bial\u0103 pentru \u00een\u021belegerea modului \u00een care noile terapii cu incretine difer\u0103 de agoni\u0219tii stabili\u021bi ai receptorilor GLP-1.<\/p>\n<p><strong>Ce domenii de cercetare investigheaz\u0103 \u00een mod obi\u0219nuit Semaglutida?<\/strong><\/p>\n<p>Studiile publicate au investigat Semaglutida \u00eentr-o gam\u0103 larg\u0103 de domenii de cercetare metabolic\u0103, inclusiv obezitatea, reglarea greut\u0103\u021bii corporale, semnalizarea a apetitului, metabolismul glucozei, diabetul de tip 2, rezultatele cardiovasculare, boala ficatului gras \u0219i biologia incretinic\u0103 pe termen lung. Baza sa extins\u0103 de dovezi o face una dintre cele mai frecvent men\u021bionate peptide \u00een cercetarea metabolic\u0103 modern\u0103.<\/p>\n<p><strong>Cum se furnizeaz\u0103 Semaglutida?<\/strong><\/p>\n<p>Acest produs este furnizat sub form\u0103 de 10 mg de Semaglutid\u0103 liofilizat\u0103 \u00eentr-un flacon steril de cercetare. Fiecare lot este \u00eenso\u021bit de un Certificat de Analiz\u0103 (COA), iar verificarea analitic\u0103 independent\u0103 de c\u0103tre ter\u021bi este disponibil\u0103 pentru loturile selectate. Produsul este destinat exclusiv cercet\u0103rii de laborator \u0219i analitice.<\/p>\n<p><strong>Pot cump\u0103ra Semaglutid\u0103 \u00een Europa?<\/strong><\/p>\n<p>Da. Expediem Semaglutid\u0103 \u00een majoritatea \u021b\u0103rilor europene folosind servicii de curierat sigure. Metodele de expediere disponibile \u0219i timpii de livrare sunt afi\u0219a\u021bi \u00een timpul finaliz\u0103rii comenzii, \u00een func\u021bie de destina\u021bia dvs.<\/p>\n<p><strong>Este acest produs destinat uzului uman?<\/strong><\/p>\n<p>Nu. Semaglutida furnizat\u0103 de Life Peptide este destinat\u0103 exclusiv utiliz\u0103rii \u00een scopuri de cercetare. Aceasta nu este destinat\u0103 consumului uman, diagnostic\u0103rii, trat\u0103rii sau prevenirii bolilor. Orice referire la studiile clinice publicate pe aceast\u0103 pagin\u0103 este inclus\u0103 exclusiv pentru a rezuma literatura \u0219tiin\u021bific\u0103 actual\u0103 privind molecula de semaglutid\u0103.<\/p>\n<h4><strong>Context de cercetare aferent<\/strong><\/h4>\n<p>Semaglutide apar\u021bine clasei de agoni\u0219ti ai receptorilor GLP-1 din cadrul cercet\u0103rii metabolice bazate pe incretin\u0103. Pentru compara\u021bia mecanic\u0103 cu agoni\u0219tii duali \u0219i tripli, consulta\u021bi-ne <strong><a href=\"http:\/\/example.test\/glp-1-metabolic-research-guide\/\" target=\"_blank\" rel=\"noopener\">Ghid de cercetare metabolic\u0103 GLP-1<\/a>.<\/strong><\/p>\n<p>R\u0103sfoie\u0219te toate compu\u0219ii din <a title=\"Categoria de cercetare metabolic\u0103.\" href=\"\/ro\/product-category\/metabolic-research\/\"><strong>Categoria de cercetare metabolic\u0103.<\/strong><\/a><\/p>\n<p>Pentru compara\u021bia c\u0103ilor metabolice:<\/p>\n<ul data-start=\"2633\" data-end=\"2702\">\n<li data-start=\"2633\" data-end=\"2671\">\n<p data-start=\"2635\" data-end=\"2671\">Agoni\u0219ti duali: \u00a0<a href=\"http:\/\/example.test\/product\/tirzepatide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Tirzepatid (GLP-1\/GIP)<\/a><\/p>\n<\/li>\n<li data-start=\"2672\" data-end=\"2702\">\n<p data-start=\"2674\" data-end=\"2702\">Agoni\u0219ti tripli: <a href=\"http:\/\/example.test\/product\/retatrutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Retatrutid\u0103 (GLP-1\/GIP\/glucagon)<\/a><\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Not\u0103: <\/strong>Acest material este doar \u00een scop educa\u021bional \u0219i nu constituie consult medical.<\/p>\n<p><strong>Renun\u021bare la r\u0103spundere:<\/strong><br \/>\nAcest produs este v\u00e2ndut exclusiv \u00een scopuri de cercetare. Nu este destinat diagnostic\u0103rii, trat\u0103rii, vindec\u0103rii sau prevenirii vreunei boli. Cump\u0103r\u0103torul \u00ee\u0219i asum\u0103 \u00eentreaga responsabilitate pentru manipularea \u0219i utilizarea corespunz\u0103toare.<\/p>","protected":false},"excerpt":{"rendered":"<p>Semaglutida 10 mg este un agonist al receptorilor GLP-1 de grad de cercetare, furnizat sub form\u0103 liofilizat\u0103 pentru uz de laborator. Fiind unul dintre cele mai amplu studiate peptide incretinice, acesta a devenit compusul de referin\u021b\u0103 pentru cercetarea privind reglarea apetitului, modificarea greut\u0103\u021bii corporale, metabolismul glucozei \u0219i semnalizarea cardiometabolic\u0103.<\/p>\n<p>||<\/p>\n<p>Puritate \u226599% | Cump\u0103ra\u021bi din Europa cu livrare \u00eencep\u00e2nd de la 5 \u20ac | Sunt disponibile op\u021biuni de livrare gratuit\u0103 | Se accept\u0103 pl\u0103\u021bi cu cardul<\/p>","protected":false},"featured_media":1236,"template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[257,254,287,248,253,139,255,247,258,246],"class_list":["post-303","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-appetite-regulation","product_tag-blood-glucose-research","product_tag-buy-semaglutide","product_tag-energy-balance","product_tag-glp-1-agonist","product_tag-glp-1-research","product_tag-incretin-signaling","product_tag-metabolic-peptide","product_tag-obesity-peptide","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/product\/303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/media\/1236"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/media?parent=303"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/product_brand?post=303"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/product_cat?post=303"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/product_tag?post=303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}